5852873
Last Update Posted: 2025-11-21
Recruiting has ended
All Genders accepted | 18 Years-64 Years |
2000 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old.
The main question it aims to answer is:
Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo.
Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up.
Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.
The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old.
The main question it aims to answer is:
Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo.
Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up.
Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.
Eligibility
Relevant conditions:
Post COVID-19 Condition, Unspecified
SARS-CoV2 Infection
COVID-19
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Nina Langeland, MD, PhD
nina.langeland@uib.no
+47-41616450
Bjorn Blomberg, MD, PhD
bjorn.blomberg@uib.no
+47-93262119
Data sourced from ClinicalTrials.gov